|  |
| --- |
| **Baseline Subject and Procedural Characteristics**  |
| **Measure** **(mean ± SD)** | **LA subjects** | **GA subjects** | **p-value\*** |
| N (total) | 32 | 10 |  |
| Age | 64.5 yr ± 10.8 | 60.5 yr ± 11.3 | 0.3 |
| Prostate volume | 37 cc ± 9.2 | 40 cc ± 9.1 | 0.5 |
| Implants/subject | 3.1 ± 1.3 | 3.2 ± 1.0 | 0.9 |
| Theater time | 17 min ± 5.2 | 17 min ± 6.0 | 0.9 |
| Pain score (VAS) | 2 ± 1.4 | 2 ± 2.0 | 0.9 |
| IPSS | 19 ± 6.2 | 23 ± 6.9 | 0.1 |
| QoL | 5 ± 0.8 | 5 ± 1.3 | 0.4 |
| **3-Month Outcomes** |
| IPSS paired subjects (N) | 18 | 9 |  |
| IPSS follow-up | 9 ± 4.3 | 10 ± 1.8 | 0.6 |
| IPSS change | -12 ± 7.3 | -12 ± 6.0 | 0.9 |
| *paired p-value* | <.0001 | <.001 |  |
| QoL paired subjects (N) | 32 | 10 |  |
| QoL follow-up | 2 ± 1.3 | 2 ± 1.0 | 0.8 |
| QoL change | -3 ± 1.6 | -3 ± 1.1 | 0.4 |
| *paired p-value* | <.0001 | <.0001 |  |

IPSS = International Prostate Symptom Score

IIEF-5 = International Index of Erectile Function

VAS = visual analogue scale

QoL = Quality of Life